Novavax COVID-19 vaccine 90.4% effective in clinical trial, company says

1 min read

Novavax announced on Monday that its COVID-19 vaccine was found to be over 90% effective overall, and offered 100% protection against moderate and severe disease in a Phase 3 clinical trial. The company said it intends to file for FDA authorization in the third quarter. 

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Stanley C. Erck, Novavax’s president and CEO said in a statement. “These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.” 


This is a developing story, please continue to check back for updates.  

Leave a Reply

Your email address will not be published.

Previous Story

Ex-Celtics player suggests Kyrie Irving's ankle injury is karma after logo stomp

Next Story

EU 'uncomfortable' with reality of war as Putin looks to 'exploit' West

Latest from Blog

withemes on instagram